Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-06-15
2010-06-15
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S001490, C424S155100, C424S178100, C424S450000, C530S338000, C530S391100
Reexamination Certificate
active
07736647
ABSTRACT:
The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells.
REFERENCES:
patent: 5756097 (1998-05-01), Landucci et al.
patent: 5762932 (1998-06-01), Kemp
patent: WO-91/14452 (1991-10-01), None
patent: WO-2005/121179 (2005-12-01), None
US 6,290,956, 09/2001, Bander (withdrawn)
Dictionary definition (medicinenet.com) of phtotoxin for ricin and abrin (p. 1).
Dictionary definition (dict.die.net) for the term “galenic” (p. 1).
Search output from ATCC website for BA 120 hybridoma (p. 1).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Jain (Scientific American pp. 58-64 (Jul. 1994)).
Chatterjee et al (Cancer lmmunol. Imunother. 38:75-82 (1994).
Dermer Biotechnology 12: 320, 1994.
Gura et al (Science 278:1041-1042 (1997)).
Seaver (Genetic Engineering 14(14):pp. 10 and 21 (1994)).
Qing et al. (Cancer Immunol. Immunther. 55:1111-1121 (2006).
Wikipedia definition of “galenic formulation” (p. 1).
Wikipedia definition of “monoclonal antibody therapy” (pp. 1-6).
Baras, JYI vol. 16 (pp. 1-6).
Stedman's Medical Dictionary, 27th Ed. definition of “trichothecium” versus “tricathecum”.
Campbell et al, Biology, 5th ed. p. 856, 1999.
Teltow et al. Antimicrob. Agents & Chemo. 23:390-396 (1983).
Life Science Dictionary definitions #8 and #10 for a peptide and a polypeptide.
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Stein, Pharmacology and Therapeutics 85: 231-236 (2000).
Stein, C.A., J. Clinical Investigation 108(5): 641-644, 2001.
Caplen, N.J., Gene Therapy 11(16): 1241-1248, 2004.
Lesley, Jayne F., et al., “Inhibition of Cell Growth by Monoclonal Anti-Transferrin Receptor Antibodies,”Molecular and Cellular Biology, vol. 5(8):1814-1821 (1985).
Li, Hongyan, et al., “The role of the transferrin-transferrin-receptor system in drug delivery and targeting,”Trends in Pharmacological Sciences, vol. 23(9):206-209 (2002).
Moura, Ivan C., et al., “A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients,”Blood, vol. 103(5):1838-1845 (2004).
Ng, Patrick P., et al., “An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells,”PNAS, vol. 99(16)10706-10711 (2002).
Shinohara, Hisashi, et al., “Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin,”International Journal of Oncology, vol. 17:643-651(2000).
Taetle, Raymond, et al., “Mechanisms of Growth Inhibition by Anti-Transferrin Receptor Monoclonal Antibodies,”Cancer Research, vol. 46:1759-1763 (1986).
Batra, Janendra K. et al., “Antitumor activity in mice of an immunotoxin-made with anti-transferrin receptor and a recombinant form ofPseudomonas exotoxin,” Proc. Natl. Acad. Sci. USA., vol. 86:8545-8549 (1989).
Brooks, Donald et al., “Phase la Trial of Murine Immunoglobulin A Antitransferrin Receptor Antibody 42/6,”Clinical Cancer Research, vol. 1:1259-1265 (1995).
Jones, Emma et al., “Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice,”Cancer Immunity, vol. 2(1):1-12 (2002).
Rammensee, Hans-Georg et al., “Antibodies against the transferrin receptor block the induction of cytotoxic T lymphocytes. A new method for antigen-specific negative selection in vitro,”Eur. J. Immunol., vol. 15:687-692 (1985).
Taetle, Raymond et al., “Effects of Monoclonal Anti-Transferrin Receptor Antibodies on in Vitro Growth of Human Solid Tumor Cells,”Cancer Research, vol. 47:2040-2044 (1987).
van Dijk, Astrid M.C. et al., “Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease,”British Journal of Haematology, vol. 107:169-175 (1999).
Weissman, Allan M. et al., “Exposure of K562 Cells to Anti-receptor Monoclonal Antibody OKT9 Results in Rapid Redistribution and Enhanced Degradation of the Transferrin Receptor,”The Journal of Cell Biology, vol. 102:951-958 (1986).
White, Suhaila et al., “Combination of Anti-Transferrin Receptor Monoclonal Antibodies Inhibit Human Tumor Cell Growth in Vitro and in Vivo: Evidence for Synergistic Antiproliferative Effects,”Cancer Research, vol. 50:6295-6301 (1990).
International Search Report for Application No. PCT/IB2006/002331, dated Mar. 14, 2007.
Bensussan Armand
Boumsell Laurence
Kadouche Jean
Bristol Lynn
Institut National de la Sante et de la Recherche Medicale (Inser
Lahive & Cockfield LLP
Monoclonal Antibodies Therapeutics
Williams, Esq. Megan E.
LandOfFree
Anti-CD71 monoclonal antibodies and uses thereof for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CD71 monoclonal antibodies and uses thereof for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD71 monoclonal antibodies and uses thereof for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4206234